1. Reply to K. Hashimoto and A. Shimomura.
- Author
-
Johnston SRD, Harbeck N, Toi M, Martin M, O'Shaughnessy J, and Rastogi P
- Abstract
Competing Interests: Stephen R. D. JohnstonHonoraria: Pfizer, Novartis, Eisai, AstraZeneca, Roche, LillyConsulting or Advisory Role: Lilly, Puma Biotechnology, Novartis, PfizerResearch Funding: Pfizer, Puma Biotechnology Nadia HarbeckStock and Other Ownership Interests: West German Study GroupHonoraria: Roche, Novartis, Amgen, Pfizer, Genomic Health, AstraZeneca, Zodiac Pharma, Pierre FabreConsulting or Advisory Role: Roche/Genentech, Novartis, Celgene, Pfizer, Lilly, Sandoz, Daiichi Sankyo, Agendia, AstraZeneca, Merck Sharp & Dohme, Odonate Therapeutics, Seattle Genetics, West German Study Group, Pierre FabreResearch Funding: Roche/Genentech, Novartis, Pfizer, Lilly, Merck Sharp & Dohme Masakazu ToiHonoraria: Novartis, TAKEDA, AstraZeneca, Eisai, Chugai Pharma, Taiho Pharmaceutical, Daiichi Sankyo, Yakult Pharmaceutical, Shimadzu, Pfizer, Konica Minolta, Lilly, Kyowa Kirin, Devicore Medical Japan, Exact Sciences, Nippon KayakuConsulting or Advisory Role: Daiichi Sankyo, Kyowa Kirin, Bertis, Athenex, Bristol-Myers Squibb, Kansai Medical Net, Terumo, Luxonus, AstraZeneca, LillySpeakers' Bureau: Pfizer, AstraZeneca, Lilly, Daiichi SankyoResearch Funding: Taiho Pharmaceutical, Chugai Pharma, Shimadzu, Astellas Pharma, AFI Technology, Japan Breast Cancer Research Group, Pfizer, Eisai, Daiichi Sankyo, AstraZeneca, Ono Pharmaceutical, Nippon Kayaku, Kyoto Breast Cancer Research NetworkPatents, Royalties, Other Intellectual Property: JP 2017-143763, WO2017/131162A1, PCT/JP2016/004374Travel, Accommodations, Expenses: Eisai, TakedaOther Relationship: Japan Breast Cancer Research Group, Kyoto Breast Cancer Research Network, Organization for Oncology and Translational Research Miguel MartinHonoraria: Roche/Genentech, Lilly, Pfizer, Novartis, Pierre FabreConsulting or Advisory Role: Roche/Genentech, Novartis, Pfizer, Lilly, AstraZeneca, Taiho Pharmaceutical, PharmaMarSpeakers' Bureau: Lilly/ImClone, Roche/Genentech, Pierre Fabre, Novartis, Roche, Puma Biotechnology Joyce O'ShaughnessyHonoraria: AstraZeneca, Lilly, AbbVie, Celgene, Eisai, Novartis, Pfizer, Agendia, Amgen, Bristol-Myers Squibb, Genentech, Genomic Health, GRAIL, Immunomedics, Heron, Ipsen, Jounce Therapeutics, Merck, Myriad Pharmaceuticals, Puma Biotechnology, Roche, Seattle Genetics, Syndax, Odonate Therapeutics, Sanofi, Samsung, Daiichi SankyoConsulting or Advisory Role: Novartis, Pfizer, Lilly, AbbVie, AstraZeneca, Celgene, Eisai, Agendia, Amgen, Bristol-Myers Squibb, Genentech, Genomic Health, GRAIL, Immunomedics, Heron, Ipsen, Jounce Therapeutics, Merck, Myriad Pharmaceuticals, Puma Biotechnology, Roche, Seattle Genetics, Syndax, Odonate Therapeutics, Sanofi, Samsung, Daiichi SankyoSpeakers' Bureau: AstraZeneca, Novartis, Lilly, PfizerResearch Funding: Seattle GeneticsTravel, Accommodations, Expenses: Celgene, Lilly, Novartis, Pfizer, AbbVie, Agendia, Amgen, Eisai, Genomic Health, GRAIL, Ipsen, Jounce Therapeutics, Myriad Pharmaceuticals, Puma Biotechnology, Seattle Genetics, AstraZeneca, Sanofi, Roche Priya RastogiTravel, Accommodations, Expenses: Genentech/Roche, Lilly, AstraZenecaNo other potential conflicts of interest were reported.
- Published
- 2021
- Full Text
- View/download PDF